Sertraline

Results: 435



#Item
141EUR J PHYS REHABIL MED 2009;45:[removed]The clinical use of drugs influencing neurotransmitters in the brain to promote motor recovery after stroke; a Cochrane systematic review

EUR J PHYS REHABIL MED 2009;45:[removed]The clinical use of drugs influencing neurotransmitters in the brain to promote motor recovery after stroke; a Cochrane systematic review

Add to Reading List

Source URL: doc.utwente.nl

Language: English - Date: 2011-08-28 15:53:26
142HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WELLBUTRIN XL® safely and effectively. See full prescribing information for WELLBUTRIN XL. WELLBUTRIN XL (bupropion

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WELLBUTRIN XL® safely and effectively. See full prescribing information for WELLBUTRIN XL. WELLBUTRIN XL (bupropion

Add to Reading List

Source URL: valeant.com

Language: English - Date: 2015-01-16 09:25:49
143Enhanced_2014_STCriteria_Dec_v1

Enhanced_2014_STCriteria_Dec_v1

Add to Reading List

Source URL: www.aetnamedicare.com

Language: English - Date: 2015-03-03 11:45:30
144ORIGINAL ARTICLE  Time to Relapse After Short- or Long-term Treatment of Severe Premenstrual Syndrome With Sertraline Ellen W. Freeman, PhD; Karl Rickels, MD; Mary D. Sammel, ScD; Hui Lin, MS; Steven J. Sondheimer, MD

ORIGINAL ARTICLE Time to Relapse After Short- or Long-term Treatment of Severe Premenstrual Syndrome With Sertraline Ellen W. Freeman, PhD; Karl Rickels, MD; Mary D. Sammel, ScD; Hui Lin, MS; Steven J. Sondheimer, MD

Add to Reading List

Source URL: archpsyc.jamanetwork.com

Language: English
145ORIGINAL ARTICLE  ONLINE FIRST Antidepressant Use During Pregnancy and Childhood Autism Spectrum Disorders

ORIGINAL ARTICLE ONLINE FIRST Antidepressant Use During Pregnancy and Childhood Autism Spectrum Disorders

Add to Reading List

Source URL: archpsyc.jamanetwork.com

Language: English
146___________________________________________________________________ 2014 Behavioral Health Medication Formulary Effective January 1, 2014 Introduction Magellan is pleased to provide the 2014 Magellan Maricopa County Beha

___________________________________________________________________ 2014 Behavioral Health Medication Formulary Effective January 1, 2014 Introduction Magellan is pleased to provide the 2014 Magellan Maricopa County Beha

Add to Reading List

Source URL: www.magellanofaz.com

Language: English - Date: 2014-01-21 15:02:11
147TREATMENT  106 Review: most selective serotonin reuptake inhibitors lead to adverse events that appear to outweigh the benefits in children

TREATMENT 106 Review: most selective serotonin reuptake inhibitors lead to adverse events that appear to outweigh the benefits in children

Add to Reading List

Source URL: ebn.bmj.com

Language: English
148RESEARCH Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials Dirk Eyding, project mana

RESEARCH Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials Dirk Eyding, project mana

Add to Reading List

Source URL: www.bmj.com

Language: English - Date: 2015-02-10 13:31:31
149Multi-criteria benefit-risk assessment using network meta-analysis Gert van Valkenhoef∗,a,b , Tommi Tervonenc , Jing Zhaoa , Bert de Brockb , Hans L. Hillegea , Douwe Postmusa a Department of Epidemiology, University M

Multi-criteria benefit-risk assessment using network meta-analysis Gert van Valkenhoef∗,a,b , Tommi Tervonenc , Jing Zhaoa , Bert de Brockb , Hans L. Hillegea , Douwe Postmusa a Department of Epidemiology, University M

Add to Reading List

Source URL: drugis.org

Language: English - Date: 2013-12-04 08:49:46
150On January 21, 2005, the Federal Circuit affirmed the district court’s dismissal of Teva’s declaratory judgment action after Pfizer failed to sue Teva for infringing U.S. Patent No. 5,248,699, which related to sertra

On January 21, 2005, the Federal Circuit affirmed the district court’s dismissal of Teva’s declaratory judgment action after Pfizer failed to sue Teva for infringing U.S. Patent No. 5,248,699, which related to sertra

Add to Reading List

Source URL: www.law.umaryland.edu

Language: English - Date: 2005-01-30 08:33:43